臨床研究等提出・公開システム

Pilot study of Boron Neutron Capture Therapy for recurrent breast cancer after radiotherapy

Study of BNCT on recurrent breast cancer

Kurosaki Hiromasa

Edogawa Hospital

2-24-18 Higashikoiwa, Edogawa-ku, Tokyo, Japan

h.kurosaki@edogawa.or.jp

Kurosaki Hiromasa

Edogawa Hospital

2-24-18 Higashikoiwa, Edogawa-ku, Tokyo, Japan

+81-3-3673-1221

h.kurosaki@edogawa.or.jp

Recruiting

Oct. 07, 2022

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1) Written consent for participation in this study has been obtained from the subject or a surrogate at the time consent is obtained.
2) The following patients with breast cancer
Patients with confirmed recurrence within or at the margins of the chest radiotherapy field and one or more measurable lesions according to RECIST guidelines (version 1.1)
Patients who have undergone radiotherapy for more than 6 months since their last radiotherapy treatment.
Patients who are not adversely affected by withdrawal of chemotherapy (including molecular-targeted agents) for more than 4 weeks prior to BNCT treatment.
Patients who are deemed capable of containing all active lesions within the irradiated area envisaged by BNCT
Patients with the longest diameter of the entire target lesion of 15 cm or less
Patients with lesions with a distance of 6 cm or less from the skin surface to the deepest part of the tumor
Patients with no evidence of serious cardiac complications on resting 12-lead ECG

1) Patients who have received more than 75 Gy of radiotherapy to the lesion area in the prior treatment of the target lesion.
2) Patients with active lesions/active overlapping cancers other than the target lesion (however, patients with distant metastases who show no tendency to enlarge and whose quality of life can be significantly improved by controlling locally recurrent lesions are not excluded)
3) Patients with measurable tumor skin exposure greater than 5 cm
4) Patients with NYHA cardiac function classification grade III or IV
5) Patients with pulmonary fibrosis or interstitial pneumonia

Both

breast cancer

Boron Neutron Capture Therapy

breast cancer

D001943

Safety: Acute adverse events for safety evaluation criteria

Efficacy: response rate, tumor shrinkage rate, progression-free survival, overall survival

+81-43-206-4706

Yes

De-identified (anonymized) or coded (pseudonymized) individual clinical trial participant data will be provided to CICS Co., Ltd. and Stella Pharma Co., Ltd. De-identified (anonymized) or coded (pseudonymized) individual clinical trial participant data would be shared when needed, upon request from a third party (including domestic/oversea person/organization/company), authorized by the principal investigator of this study(or another person/organization/company licensed by the principal investigator).

none